PK/PD and Clinical Relationships of Pharmasin® / Tylovet® Premix (Tylosin Phosphate) Administered to Pigs for the Treatment of Necrotic Enteritis

reading time
Poster | 09.07.2022
Poster presented by Ulrich Klein at ESPHM 2022, Budapest, Hungary

The relationship between the pharmacokinetics (PK) and the pharmacodynamics (PD) of a product influence its efficacy. The PK/PD relationship of Pharmasin® / Tylovet® (tylosin phosphate) was examined in two trials, one conducted in Brazil and the other in Italy. In both trials the colon content concentrations (CCC) of tylosin were found to be high, exceeding the MIC values of the majority of the Clostridium perfringens strains.

Download the poster here 


global presence

Local support from a global company

Huvepharma® has a distribution network which covers more than 90 countries in 6 continents. Find your nearest Huvepharma® representative today.
Find your local contact
about us


Huvepharma® is a fast-growing, global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health and nutrition products.
more about us

Change country

The Huvepharma® distribution network covers 90 countries in 6 continents. Please select a country from the list below to see the products and services available in that region.

To view all products and services, select Global from the dropdown menu or click .




North America


South America

Change language

Huvepharma has a remarkable distribution network which covers 90 countries in 6 continents. To offer you the best services, we ask you to select your country.


United States

Click here to visit the local website or close this popup to stay on the global website.

Your browser is out of date!

Update your browser to view this website correctly. Update my browser now